Clearside Biomedical to Host Virtual Key Opinion Leader Event on the Use and Versatility of Suprachoroidal Drug Delivery

Core Insights - Clearside Biomedical, Inc. is hosting a virtual key opinion leader (KOL) event on July 24, 2024, focusing on the advancements in suprachoroidal drug delivery for retinal diseases [1][12] - The event will feature presentations from leading retinal specialists, including insights on the company's SCS injection platform and its applications in treating neovascular age-related macular degeneration (wet AMD) [3][12] Company Overview - Clearside Biomedical is a biopharmaceutical company specializing in the delivery of therapies to the back of the eye through the suprachoroidal space (SCS) [5] - The company's SCS Microinjector® allows for a non-surgical, repeatable procedure aimed at delivering various therapies to the macula, retina, or choroid, potentially improving vision in patients with serious eye diseases [5] - Clearside's lead product, CLS-AX, is currently in Phase 2b clinical testing for wet AMD, while its first product, XIPERE®, is already available in the U.S. through a commercial partner [5] Event Details - The KOL event will include a live question-and-answer session with retinal experts and Clearside senior management, providing a platform for discussing real-world experiences with suprachoroidal drug delivery [3][12] - Notable speakers include Dr. David M. Brown, Dr. Victor Chong, and Dr. Glenn C. Yiu, who will share their expertise and insights on the implications of the SCS technology in retinal treatments [3][8][12] Research and Development Focus - The event will highlight the broad applicability of the SCS technology and ongoing clinical programs, emphasizing potential future development opportunities for Clearside [12] - The company is also exploring partnerships to enhance its SCS injection platform with other ophthalmic therapeutic innovations [5]